[go: up one dir, main page]

UY30670A1 - Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones. - Google Patents

Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.

Info

Publication number
UY30670A1
UY30670A1 UY30670A UY30670A UY30670A1 UY 30670 A1 UY30670 A1 UY 30670A1 UY 30670 A UY30670 A UY 30670A UY 30670 A UY30670 A UY 30670A UY 30670 A1 UY30670 A1 UY 30670A1
Authority
UY
Uruguay
Prior art keywords
new
applications
compositions containing
compounds
pirazoline
Prior art date
Application number
UY30670A
Other languages
English (en)
Inventor
Rico Joseph Gerace
Reitz David Bruce
Mahoney William Matthew
Long Scott Allen
Hockerman Landis Susan
Xiangyang Chen
Barbieri Graciela
Marvin Jay Meyers
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30670A1 publication Critical patent/UY30670A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion está dirigida a nuevos compuestos pirimidina bicíclicos de Formula (I) o a una forma o composicion de ésta como inhibidores de las interacciones de ATP-protein quinasa, donde los sustituyentes en cada lado del enlace doble iminometilo en la Formula (I) pueden estar en la configuracion E o Z; y donde R1, R2, R3 y R4 son tal como se definen aquí.
UY30670A 2006-10-31 2007-10-29 Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones. UY30670A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86360606P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
UY30670A1 true UY30670A1 (es) 2008-05-31

Family

ID=39027523

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30670A UY30670A1 (es) 2006-10-31 2007-10-29 Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.

Country Status (40)

Country Link
US (3) US7781428B2 (es)
EP (1) EP2089367B1 (es)
JP (1) JP4977760B2 (es)
KR (1) KR101107800B1 (es)
CN (1) CN101541757A (es)
AP (1) AP2527A (es)
AR (1) AR063529A1 (es)
AT (1) ATE537151T1 (es)
AU (1) AU2007315884B2 (es)
BR (1) BRPI0717937A2 (es)
CA (1) CA2667966C (es)
CL (1) CL2007003154A1 (es)
CO (1) CO6160307A2 (es)
CR (1) CR10725A (es)
CU (1) CU23779B7 (es)
CY (1) CY1112311T1 (es)
DK (1) DK2089367T3 (es)
EA (1) EA016370B1 (es)
ES (1) ES2375877T3 (es)
GE (1) GEP20115239B (es)
GT (1) GT200700096A (es)
HN (1) HN2007000437A (es)
HR (1) HRP20120078T1 (es)
IL (1) IL198241A0 (es)
MA (1) MA30821B1 (es)
MX (1) MX2009004662A (es)
MY (1) MY145795A (es)
NI (1) NI200900071A (es)
NO (1) NO20091741L (es)
NZ (1) NZ575923A (es)
PE (1) PE20081472A1 (es)
PL (1) PL2089367T3 (es)
PT (1) PT2089367E (es)
RS (2) RS20090208A (es)
SI (1) SI2089367T1 (es)
TN (1) TN2009000160A1 (es)
TW (1) TWI357327B (es)
UA (1) UA92670C2 (es)
UY (1) UY30670A1 (es)
WO (1) WO2008053300A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
EP2597089A1 (en) * 2009-10-29 2013-05-29 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
US8957052B2 (en) 2010-05-10 2015-02-17 Universite Paris Descartes Methods and compositions for the treatment of fluid accumulation in and/or under the retina
WO2011141848A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
WO2011157798A1 (en) 2010-06-16 2011-12-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for stimulating reepithelialisation during wound healing
CN102372710A (zh) * 2010-08-18 2012-03-14 山东轩竹医药科技有限公司 作为盐皮质激素受体拮抗剂的并环类化合物
WO2012048022A2 (en) * 2010-10-05 2012-04-12 Nova Southeastern University Methods and compositions for therapeutic modulation of aldosterone levels in heart disease
CN106536491B (zh) 2014-06-30 2018-12-18 阿斯利康(瑞典)有限公司 作为盐皮质激素受体调节剂的苯并噁嗪酮酰胺
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018045149A1 (en) 2016-09-02 2018-03-08 Bristol-Myers Squibb Company Substituted tricyclic heterocyclic compounds
US11059784B2 (en) 2017-08-09 2021-07-13 Bristol-Myers Squibb Company Oxime ether compounds
US11046646B2 (en) 2017-08-09 2021-06-29 Bristol-Myers Squibb Company Alkylphenyl compounds
CN109051490B (zh) 2018-09-18 2024-07-23 深圳市鲸仓科技有限公司 可移动式密集存拣装置
US20230151425A1 (en) 2020-03-11 2023-05-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
EP4395785A1 (en) 2021-08-31 2024-07-10 Inserm (Institut National de la Santé et de la Recherche Scientifique) Methods for the treatment of ocular rosacea
CN113679716B (zh) 2021-10-13 2024-03-26 史大永 溴酚-吡唑啉化合物在治疗猫冠状病毒疾病中的应用
CN114230457B (zh) * 2022-01-04 2023-06-09 中山大学 一类2-亚苄基四氢萘酮衍生物及其制备方法和应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1086068A (en) * 1964-09-02 1967-10-04 Ici Ltd Process for the whitening of polymeric materials and nitrogen-containing polycyclic compounds for use therein
BE789948A (fr) * 1971-10-13 1973-04-11 Sandoz Sa Nouveaux derives du pyrazole, leur preparation et leur application comme medicaments
US3816438A (en) * 1972-12-22 1974-06-11 Sandoz Ag 2h(1)-benzothiepino(5,4-c)-pyrazoles and(1)-benzothiopyrano(4,3-c)-pyrazoles
US3843666A (en) * 1973-05-29 1974-10-22 Sandoz Ag Process for preparing substituted indeno,naphtho and cyclohepta pyrazoles
US4866025A (en) * 1988-09-30 1989-09-12 Eastman Kodak Company Thermally-transferable fluorescent diphenylpyrazolines
EP0623122B1 (en) * 1992-01-23 1997-03-05 Pfizer Inc. Benzopyran and related LTB4-antagonists.
GB9318691D0 (en) 1993-09-09 1993-10-27 Merck Sharp & Dohme Therapeutic agents
ID16283A (id) 1996-03-20 1997-09-18 Astra Pharma Prod Senyawa yang berguna dibidang farmasi
JP2001501180A (ja) * 1996-09-05 2001-01-30 アストラ・フアーマシユウテイカルズ・リミテツド 新規なアリールピリダジン
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
IT1292092B1 (it) 1997-06-05 1999-01-25 Geange Ltd Impiego di derivati eterociclici aromatici azotati nel trattamento topico di affezioni di tessuti epiteliali
CN1311678A (zh) 1998-04-30 2001-09-05 巴斯福股份公司 具有蛋白激酶活性的取代的三环吡唑衍生物
US6432974B1 (en) * 2000-02-04 2002-08-13 Wyeth Pyrrolo-isoquinoline and tetra-hydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-HT7 receptor
ATE448207T1 (de) 2002-03-08 2009-11-15 Merck & Co Inc Mitotische kinesin-hemmer
AU2003230581A1 (en) 2002-03-15 2003-09-29 Eli Lilly And Company Dihydroindol-2-one derivatives as steroid hormone nuclear receptor modulators
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
ATE339419T1 (de) 2002-08-02 2006-10-15 Vertex Pharma Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
JP4519657B2 (ja) 2002-09-18 2010-08-04 ファイザー・プロダクツ・インク 形質転換成長因子(tgf)阻害剤としての新規なピラゾ−ル化合物
EP1597254A1 (en) 2003-01-22 2005-11-23 Eli Lilly and Company Indole-derivative modulators of steroid hormone nuclear receptors
CN1918151A (zh) 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
JP2007230869A (ja) 2004-04-05 2007-09-13 Takeda Chem Ind Ltd アルドステロン受容体拮抗剤
WO2006010142A2 (en) 2004-07-14 2006-01-26 Ligand Pharmaceuticals, Inc. Mineralocorticoid receptor modulator compounds, processes for their preparation, and their use
HUE041596T2 (hu) 2004-07-30 2019-05-28 Exelixis Inc Pirrol származékok mint gyógyászati szerek
EP1844020B1 (en) 2005-01-10 2017-09-06 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptor ligands
JPWO2006077821A1 (ja) 2005-01-19 2008-06-19 大日本住友製薬株式会社 アルドステロン受容体調節剤としての芳香族スルホン化合物
CA2594662A1 (en) 2005-02-10 2006-08-17 Merck & Co., Inc. Mitotic kinesin inhibitors

Also Published As

Publication number Publication date
CU23779B7 (es) 2012-02-15
MX2009004662A (es) 2009-05-22
RS20090208A (en) 2010-06-30
US7781428B2 (en) 2010-08-24
CL2007003154A1 (es) 2008-05-09
JP4977760B2 (ja) 2012-07-18
EA200970341A1 (ru) 2009-10-30
BRPI0717937A2 (pt) 2013-12-03
KR101107800B1 (ko) 2012-01-25
TN2009000160A1 (fr) 2010-10-18
HRP20120078T1 (hr) 2012-02-29
ES2375877T3 (es) 2012-03-07
CO6160307A2 (es) 2010-05-20
US20120035131A1 (en) 2012-02-09
CY1112311T1 (el) 2015-12-09
TWI357327B (en) 2012-02-01
CN101541757A (zh) 2009-09-23
RS52203B (en) 2012-10-31
SI2089367T1 (sl) 2012-02-29
AP2009004822A0 (en) 2009-04-30
UA92670C2 (ru) 2010-11-25
CR10725A (es) 2009-05-12
AU2007315884A1 (en) 2008-05-08
NI200900071A (es) 2010-03-08
TW200822924A (en) 2008-06-01
EP2089367B1 (en) 2011-12-14
AP2527A (en) 2012-12-06
MA30821B1 (fr) 2009-10-01
US20080167294A1 (en) 2008-07-10
AR063529A1 (es) 2009-01-28
NO20091741L (no) 2009-05-29
EP2089367A1 (en) 2009-08-19
IL198241A0 (en) 2009-12-24
JP2010508257A (ja) 2010-03-18
PT2089367E (pt) 2012-02-01
GEP20115239B (en) 2011-06-10
MY145795A (en) 2012-04-30
KR20090060371A (ko) 2009-06-11
AU2007315884B2 (en) 2012-10-04
NZ575923A (en) 2011-01-28
DK2089367T3 (da) 2012-02-06
PE20081472A1 (es) 2008-10-18
CA2667966C (en) 2011-08-02
GT200700096A (es) 2010-07-15
HN2007000437A (es) 2011-01-17
PL2089367T3 (pl) 2012-04-30
CU20090058A7 (es) 2011-07-11
ATE537151T1 (de) 2011-12-15
WO2008053300A1 (en) 2008-05-08
US20100280016A1 (en) 2010-11-04
CA2667966A1 (en) 2008-05-08
EA016370B1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
UY30670A1 (es) Nuevos compuestos de pirazolina, composiciones conteniéndolos y aplicaciones.
CO6321276A2 (es) Derivados de tiazol usados como inhibidores de pi3- cinasa
UY30600A1 (es) Compuestos novedosos
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
DK2074120T3 (da) Tropan-forbindelser
SV2011003855A (es) Heteroarilos sustituidos
PE20151781A1 (es) Piridonamidas como moduladores de canales de sodio
PE20152033A1 (es) Heterociclos bicicliclos como inhibidores de fgfr
CR10027A (es) Nuevos derivados de pirrol fusionado
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
CR20110381A (es) Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2
UY31183A1 (es) Derivados de pirazinona y procesos para su preparación
UY28756A1 (es) Compuestos
UY29486A1 (es) Compuestos utiles en terapia
CY1109766T1 (el) Παραγωγα αζαπεπτιδιου ως αναστολεις πρωτεασης hiv
CO6551705A2 (es) Derivados de 3.4.4a.10b- tetrahidro-1h-tiopirano-[4.3-c]- isoquinolina
UY30856A1 (es) Nuevos derivados de 2,4 dianilinopirimidinas, su preparacion, como medicamentos, composiciones farmacéuticas y principalmente como inhibidores de ikk
UY32411A (es) DERIVADOS DE 4-AMINO-7,8-DIHIDROPIRIDO [4,3-d] PIRIMIDIN-5 (6H)-ONA
NI201100218A (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
UY32553A (es) Nuevos derivados de la pirrolidinadiona espiroheterocíclicos 3-sustituidos
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
UY32747A (es) 2-carboxamida-cicloamino-ureas sustituidas
UY32748A (es) 2-carboxamida-cicloamino-ureas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170728